Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $7 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $3 |
| Gross Profit | $0 | $0 | $0 | $3 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $17 | $19 | $18 | $53 |
| G&A Expenses | $7 | $7 | $8 | $10 |
| SG&A Expenses | $7 | $7 | $8 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $24 | $26 | $26 | $63 |
| Operating Income | -$24 | -$26 | -$26 | -$59 |
| % Margin | – | – | – | -860.7% |
| Other Income/Exp. Net | $3 | $4 | $3 | $5 |
| Pre-Tax Income | -$21 | -$22 | -$23 | -$54 |
| Tax Expense | $0 | $0 | $0 | -$6 |
| Net Income | -$21 | -$22 | -$23 | -$48 |
| % Margin | – | – | – | -708.4% |
| EPS | -0.99 | -1.05 | -1.08 | 2.41 |
| % Growth | 5.7% | 2.8% | -144.8% | – |
| EPS Diluted | -0.99 | -1.05 | -1.08 | 2.41 |
| Weighted Avg Shares Out | 21 | 21 | 21 | 19 |
| Weighted Avg Shares Out Dil | 21 | 21 | 21 | 19 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $3 | $5 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $1 | $0 | $0 | -$8 |
| EBITDA | -$20 | -$26 | -$26 | -$63 |
| % Margin | – | – | – | -914.9% |